Skip to Main Content

Paper Details

Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer.
Gynecologic Oncology
12
2020
DNIB0600A, LIFA, PSOC, Patients, Pulmonary toxicities, alanine, alanine aminotransferase, alopecia, anemia, anti-NaPi2b, aspartate, aspartate aminotransferase, bevacizumab, carboplatin, diarrhea, fatigue, hypomagnesaemia, lifastuzumab vedotin, nausea, neutropenia, ovarian cancer, patient, patients, peripheral neuropathy, platinum, platinum-sensitive recurrent ovarian cancer, pneumonitis, sensitive, thrombocytopenia, vomiting
Author NameAffiliation
Michael J BirrerUniversity of Alabama
  • 1 - 1

Datasets

Release 1.2